| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
16,577 |
13,985 |
$525K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,763 |
2,404 |
$107K |
| 90832 |
Psychotherapy, 30 minutes with patient |
1,499 |
534 |
$32K |
| 99442 |
|
800 |
710 |
$22K |
| 87428 |
|
1,118 |
1,015 |
$18K |
| 90834 |
Psychotherapy, 45 minutes with patient |
270 |
154 |
$10K |
| 99443 |
|
171 |
152 |
$10K |
| 99441 |
|
379 |
300 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
735 |
549 |
$7K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
113 |
106 |
$7K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
83 |
81 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
631 |
553 |
$4K |
| 36415 |
Collection of venous blood by venipuncture |
2,421 |
2,033 |
$4K |
| 92552 |
|
304 |
287 |
$4K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
28 |
26 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
328 |
142 |
$2K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
185 |
171 |
$2K |
| 90791 |
Psychiatric diagnostic evaluation |
24 |
24 |
$2K |
| G0511 |
Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month |
571 |
483 |
$2K |
| 80305 |
|
439 |
192 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
14 |
13 |
$919.67 |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
32 |
13 |
$860.19 |
| 90686 |
|
105 |
104 |
$805.30 |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
16 |
15 |
$744.46 |
| 0011A |
|
33 |
26 |
$707.69 |
| 0012A |
|
18 |
18 |
$671.06 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
26 |
21 |
$550.49 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
32 |
32 |
$426.04 |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
59 |
31 |
$377.05 |
| 99422 |
|
22 |
21 |
$304.51 |
| 99177 |
|
83 |
82 |
$295.64 |
| 91301 |
|
69 |
57 |
$96.94 |
| 81002 |
|
13 |
13 |
$10.03 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
21 |
19 |
$0.00 |
| 99000 |
|
144 |
136 |
$0.00 |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
26 |
26 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
14 |
13 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
34 |
33 |
$0.00 |
| 1000F |
|
211 |
190 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
82 |
82 |
$0.00 |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
21 |
19 |
$0.00 |
| 97014 |
|
60 |
34 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
52 |
52 |
$0.00 |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
51 |
35 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
32 |
32 |
$0.00 |
| A0999 |
Unlisted ambulance service |
19 |
14 |
$0.00 |
| 82607 |
|
16 |
16 |
$0.00 |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
51 |
17 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
74 |
73 |
$0.00 |
| 90680 |
|
14 |
13 |
$0.00 |
| 97010 |
|
19 |
12 |
$0.00 |
| 99072 |
|
2,259 |
1,961 |
$0.00 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
753 |
631 |
$0.00 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12 |
12 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
46 |
31 |
$0.00 |
| 80061 |
Lipid panel |
51 |
50 |
$0.00 |
| 4551F |
|
199 |
176 |
$0.00 |
| A0425 |
Ground mileage, per statute mile |
69 |
64 |
$0.00 |
| 90670 |
|
32 |
29 |
$0.00 |
| 98940 |
|
81 |
44 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
20 |
20 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
133 |
76 |
$0.00 |
| 97012 |
|
58 |
33 |
$0.00 |
| 84439 |
|
16 |
16 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
23 |
22 |
$0.00 |
| 1033F |
|
14 |
12 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
13 |
13 |
$0.00 |
| 90837 |
Psychotherapy, 53 minutes with patient |
58 |
40 |
$0.00 |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
111 |
57 |
$0.00 |